<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>12</volume><submitter>Cunningham CC</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>MicroRNAs (miRNAs) are small non-coding RNAs which have been implicated as potential biomarkers or therapeutic targets in autoimmune diseases. This study examines circulatory miRNAs in RA patients and further investigates if a serum miRNA signature precedes clinical manifestations of disease in arthralgia or "at-risk individuals".&lt;h4>Methods&lt;/h4>Serum was collected from HC subjects (N = 20), RA patients (N = 50), and arthralgia subjects (N = 10), in addition to a subgroup of the RA patients post-methotrexate (MTX) (N = 18). The FirePlex miRNA Immunology-V2 panel was selected for multiplex analysis of 68 miRNAs in each sample. DNA intelligent analysis (DIANA)-mirPath and Ingenuity Pathway Analysis (IPA) software were used to predict pathways targeted by the dysregulated m</pubmed_abstract><journal>Frontiers in immunology</journal><pagination>633201</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7966707</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Serum miRNA Signature in Rheumatoid Arthritis and "At-Risk Individuals".</pubmed_title><pmcid>PMC7966707</pmcid><pubmed_authors>Wade S</pubmed_authors><pubmed_authors>Floudas A</pubmed_authors><pubmed_authors>Cregan S</pubmed_authors><pubmed_authors>Cunningham CC</pubmed_authors><pubmed_authors>McGarry T</pubmed_authors><pubmed_authors>Veale DJ</pubmed_authors><pubmed_authors>Orr C</pubmed_authors><pubmed_authors>Fearon U</pubmed_authors></additional><is_claimable>false</is_claimable><name>Serum miRNA Signature in Rheumatoid Arthritis and "At-Risk Individuals".</name><description>&lt;h4>Background&lt;/h4>MicroRNAs (miRNAs) are small non-coding RNAs which have been implicated as potential biomarkers or therapeutic targets in autoimmune diseases. This study examines circulatory miRNAs in RA patients and further investigates if a serum miRNA signature precedes clinical manifestations of disease in arthralgia or "at-risk individuals".&lt;h4>Methods&lt;/h4>Serum was collected from HC subjects (N = 20), RA patients (N = 50), and arthralgia subjects (N = 10), in addition to a subgroup of the RA patients post-methotrexate (MTX) (N = 18). The FirePlex miRNA Immunology-V2 panel was selected for multiplex analysis of 68 miRNAs in each sample. DNA intelligent analysis (DIANA)-mirPath and Ingenuity Pathway Analysis (IPA) software were used to predict pathways targeted by the dysregulated m</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021</publication><modification>2025-04-18T16:39:07.56Z</modification><creation>2025-04-07T03:58:40.689Z</creation></dates><accession>S-EPMC7966707</accession><cross_references><pubmed>33746971</pubmed><doi>10.3389/fimmu.2021.633201</doi></cross_references></HashMap>